IL-1-targeted therapies have been shown to improve cardiovascular outcomes in clinical trials in patients with or at risk for acute myocardial infarction, heart failure, and recurrent pericarditis (Ridker and Everett, 2017; Grebe and Hoss, 2018; Abbate and Toldo, 2020). The gene discussed is IL1B; the disease is pericarditis.